CSIMarket
 
Kezar Life Sciences Inc   (KZR)
Other Ticker:  
 
 
Price: $1.0300 $-0.02 -1.905%
Day's High: $1.135 Week Perf: 14.93 %
Day's Low: $ 1.02 30 Day Perf: 4.09 %
Volume (M): 1,312 52 Wk High: $ 5.96
Volume (M$): $ 1,351 52 Wk Avg: $1.80
Open: $1.05 52 Wk Low: $0.67



 Market Capitalization (Millions $) 75
 Shares Outstanding (Millions) 73
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 2

Kezar Life Sciences Inc
Kezar Life Sciences Inc. is a biotechnology company that was founded in 2015 and is headquartered in South San Francisco, California. The company is focused on developing new therapies for autoimmune diseases and cancer by targeting the immune system. Kezar is dedicated to discovering and developing novel small molecule therapeutics that modulate the immune system and address unmet medical needs.

Kezares lead program is focused on the development of KZR-616, a selective immunoproteasome inhibitor, which is being developed for the treatment of autoimmune diseases such as lupus nephritis, dermatomyositis, and polymyositis. It is also being developed for the treatment of severe COVID-19 patients with acute respiratory distress syndrome (ARDS).

The company's approach is based on the concept of selective immunoproteasome inhibition. The immunoproteasome is a complex of protein-degrading enzymes that are highly expressed in immune cells and play a critical role in immune system function. By selectively inhibiting the immunoproteasome, Kezar believes it can develop therapeutics that help restore balance to the immune system in autoimmune disease and enhance the immune system in cancer.

In addition to KZR-616, Kezar has a pipeline of additional compounds that target different aspects of the immune system. These include small molecule inhibitors of other proteolytic complexes, such as the caspase-1 inflammasome for the treatment of inflammatory diseases.

Kezar has an experienced management team, with a track record of drug development success. The company has raised over $103 million in venture capital funding, and in 2018, it went public on the NASDAQ stock exchange under the ticker symbol KZR.

Kezares approach to immunotherapy has the potential to transform the way autoimmune diseases and cancer are treated. The company is dedicated to bringing its innovative therapeutics to patients with unmet medical needs around the world.


   Company Address: 4000 Shoreline Court South San Francisco 94080 CA
   Company Phone Number: 822-5600   Stock Exchange / Ticker: NASDAQ KZR
   KZR is expected to report next financial results on March 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Kezar Life Sciences Inc

Kezar Life Sciences Inc. Achieves Impressive Revenue of $7 Million in Latest Financial Report



Kezar Life Sciences Inc, a pharmaceutical company aiming to develop novel treatments for autoimmune diseases, has recently reported disappointing financial results. Despite generating $7 million in revenue in the most recent fiscal period, the company experienced a significantly larger net deficit of $-23.103 million, surpassing the previous year's deficit of $-17.847 million. These concerning figures, coupled with the stock's poor performance, highlight the company's inherent bearish tendencies.
Financial Woes:
Upon a closer analysis of Kezar Life Sciences Inc's financials, it becomes apparent that the company is struggling to maintain profitability. The net deficit of $-23.103 million is a clear indicator of the company's inability to manage its expenses effectively and generate consistent revenue streams. Despite recording a revenue of $7 million, the substantial financial loss signifies a lack of control over costs, leading to a negative bottom line.

Kezar Life Sciences Inc

Kezar Life Sciences Inc. Reveals Operating Shortfall in Q2 2023: What It Means for the Company's Future

Investors Remain Skeptical as Kezar Life Sciences Reports Operating Shortfall and Net Loss in Q2 2023
Kezar Life Sciences Inc, an emerging growth business, has not witnessed any adjustments at the revenue during the earnings cycle of fiscal April to June 2023. However, investors are becoming increasingly concerned about the company's operating shortfall, which reached $-26.784 million in the same period. Although the business has not yet reported its top-line, it is essential to evaluate its current efforts by comparing them to the second quarter of 2022 when Kezar reported an operating shortfall of $-16.323 million.
While the absence of top-line figures is worrying, the most significant takeaway from the fiscal span ending on June 30, 2023, is the notable net loss of $-24.308 million. This loss expanded considerably from $-16.187 million recorded in the second quarter of 2022. Kezar Life Sciences faces a challenging future, as investors anxiously await the release of the company's next financial report on November 09, 2023.

Kezar Life Sciences Inc

Overcoming Operating Shortfalls, Kezar Life Sciences Sees Promising Growth Prospects

Investors and shareholders of Kezar Life Sciences Inc can rejoice as the company prepares to report their next financial earnings on August 10, 2023. Despite the operating shortfall and extension of previous year's shortfall, shareholders have shown confidence in the business by not assuming any modifications during the January to March 31 2023 earnings season.
The resilience of Kezar Life Sciences has been a major talking point in the industry, especially with the notable backdrop of a global pandemic and its uncertain market impact on businesses. Even with the operating shortfall that has been observed in the past year, Kezar Life Sciences is still a company with great potential for growth.






 

Kezar Life Sciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com